![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1391926
¼¼°è ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå : °Ë»ç À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°Frasier Syndrome Market, By Test Type (Genetic Testing, Ultrasound Testing, Others), By End User (Hospitals, Diagnostic Centers, Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) |
ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå ±Ô¸ð´Â 2023³â 1¾ï 4,120¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 2¾ï 50¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 5.1%ÀÔ´Ï´Ù.
º¸°í ´ë»ó ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁسâ | 2022³â | 2023³â ½ÃÀå ±Ô¸ð | 1¾ï 4,120¸¸ ´Þ·¯ |
°ú°Å µ¥ÀÌÅÍ | 2018-2021³â | ¿¹Ãø ±â°£ | 2023-2030³â |
¿¹Ãø ±â°£ÀÇ CAGR | 5.10% | 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø | 2¾ï 50¸¸ ´Þ·¯ |
ÇÁ·¹ÀÌÀú ÁõÈıº(FS)Àº ½ÅÀå°ú ¼ºÀû ¹ß´Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â µå¹® À¯Àü¼º ÁúȯÀÔ´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀº ¸»±â ½ÅºÎÀüÀ¸·Î ÁøÇàµÇ´Â ½ÅÀå Áúȯ°ú ¿©¼ºÀÇ ¿ù°æÁֱ⠺ÎÁ·À¸·Î À̾îÁö´Â ¼º¼± Çü¼º ºÎÀüÀ» Ư¡À¸·ÎÇÕ´Ï´Ù.
1964³â¿¡ ÇÁ¶ó´Ù ¹Ú»ç°¡ ÇÁ·¹ÀÌÀú ÁõÈıºÀ̶ó´Â ´Ü¾î¸¦ ¸¸µé¾ú½À´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀº 11¹ø ¿°»öü ´ÜÆÈ¿¡ ÀÖ´Â WT1 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÌ À¯ÀüÀÚ´Â ¹è¾Æ ¹ß»ý °úÁ¤¿¡¼ ½ÅÀå°ú »ý½Ä¼±ÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. WT1 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ´Â Á¤»óÀûÀÎ ¼¼Æ÷ °úÁ¤À» ÆÄ±«Çϰí ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Æ¯Â¡ÀûÀΠƯ¡À» °¡Á®¿É´Ï´Ù.
ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ ¹ßº´·üÀº Ãâ»ý 100,000¸í Áß 1¸íÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÁÖ·Î ¿©¼º¿¡°Ô ¹ßº´ÇÏÁö¸¸ µå¹°°Ô ³²¼º¿¡°Ôµµ ¹ßº´ »ç·Ê°¡ º¸°íµÇ¾ú½À´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Áø´ÜÀº ÀÓ»ó Æ¯Â¡, À¯ÀüÀÚ °Ë»ç ¹× ½ÅÀå Á¶Á÷ÀÇ º´¸® Á¶Á÷ ÇÐÀû °Ë»ç¸¦ ±â¹ÝÀ¸·Î ¼öÇàµË´Ï´Ù.
ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ù°, À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡Çϰí Áøº¸µÈ Áø´Ü ±â¼úÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Áø´Ü·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú À¯ÀüÀÚ °Ë»ç¿Í ½ºÅ©¸®´×¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
´ÙÀ½À¸·Î, ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ À¯º´·ü Áõ°¡µµ ½ÃÀå È®´ë¿¡ ±â¿©ÇÕ´Ï´Ù. È¿°úÀûÀÎ ½ÅÀå ´ëü ¿ä¹ý°ú Àå±â °ü¸® Àü·«ÀÇ Çʿ伺À¸·Î ÀÎÇØ Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ź»ýÇß½À´Ï´Ù.
±×·¯³ª ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåµµ ÀÏÁ¤ÇÑ ¾ïÁ¦¿äÀο¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÀÌ µå¹® Áúº´¿¡ ´ëÇÑ °Ç° °ü¸® Àü¹®°¡¿Í ÀÏ¹Ý ½Ã¹ÎÀÇ ÀνÄÀÌ Á¦ÇÑÀûÀ̹ǷΠ°ú¼Ò Áø´Ü ¹× Ä¡·á Áö¿¬À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡, À¯ÀüÀÚ °Ë»ç³ª Àü¹®ÀûÀÎ Ä¡·á¿¡ µå´Â °í°¡ÀÇ ºñ¿ëÀÌ È¯ÀÚ³ª ±× °¡Á·¿¡°Ô ÀÖ¾î¼ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸Çϰí ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå¿¡´Â ¸î °¡Áö ±âȸ°¡ ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·áÁ¦¿Í °³ÀÎÈµÈ ÀÇ·á Á¢±Ù¹ýÀÇ °³¹ßÀº ÇÁ·¹ÀÌÀú ÁõÈıº ȯÀÚÀÇ ¿¹ÈÄ °³¼±¿¡ À¯¸ÁÇÕ´Ï´Ù. °Ô´Ù°¡ ¿¬±¸±â°ü, Á¦¾à±â¾÷, Áö¿ø´Üü°¡ Çù·ÂÇÔÀ¸·Î½á º¸´Ù ¿ì¼öÇÑ Áø´Ü Åø°ú Ä¡·á¹ýÀÇ ¿¬±¸°¡ ÃËÁøµÉ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.
The Frasier syndrome Market size is expected to reach US$ 200.5 Mn by 2030, from US$ 141.2 Mn in 2023, at a CAGR of 5.1% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 141.2 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 5.10% | 2030 Value Projection: | US$ 200.5 Mn |
Frasier syndrome (FS) is a rare genetic disorder that affects the kidneys and sexual development. It is characterized by the presence of kidney disease, which can progress to end-stage renal disease, and the development of gonadal dysgenesis, leading to the absence of menstrual cycles in females.
Dr. Prader in 1964 coined the term Frasier syndrome. It is caused by mutations in the WT1 gene located on the short arm of chromosome 11. This gene plays a crucial role in the development of the kidneys and gonads during embryogenesis. Mutations in the WT1 gene disrupt normal cellular processes, leading to the characteristic features of Frasier syndrome.
The incidence of Frasier syndrome is estimated to be around 1 in 100,000 live births. It predominantly affects females, although rare cases have been reported in males as well. The diagnosis of Frasier syndrome is based on clinical features, genetic testing, and histopathological examination of kidney tissue.
The market for Frasier syndrome is driven by several factors. Firstly, rising awareness about genetic disorders and the availability of advanced diagnostic techniques have led to an increased diagnosis rate of Frasier syndrome. This has resulted in a growing demand for genetic tests and screenings, driving market growth.
Secondly, the increasing prevalence of Frasier syndrome has also contributed to market expansion. The need for effective renal replacement therapies and long-term management strategies has created a demand for innovative treatment options.
However, the market for Frasier syndrome faces certain restraints as well. Limited awareness among healthcare professionals and the general public about this rare disorder can lead to underdiagnosis and delayed treatment. Moreover, the high cost of genetic testing and specialized treatments poses a challenge for patients and their families.
Despite these challenges, the market for Frasier syndrome presents several opportunities. The development of targeted therapies and personalized medicine approaches holds promise for improved outcomes in patients with Frasier syndrome. Furthermore, collaborations between research institutions, pharmaceutical companies, and advocacy groups can help drive research on better diagnostic tools and treatment modalities.
Frasier Syndrome Market Segmentation: